Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Defining drug-free remission of skin disease in patients with plaque psoriasis.

Armstrong AW, Blauvelt A, Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A.

Br J Dermatol. 2019 Nov 9. doi: 10.1111/bjd.18694. [Epub ahead of print]

PMID:
31705649
2.

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA.

Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, Szumski A.

Psoriasis (Auckl). 2018 Oct 8;8:65-74. doi: 10.2147/PTT.S169333. eCollection 2018.

3.

Systemic corticosteroid use in psoriasis: a national survey of board-certified dermatologists.

Secrest AM, Elkeeb DM, Petron B, Elsensohn A, Edwards LD, Krueger GG, Duffin KC.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e116-e117. doi: 10.1111/jdv.15291. Epub 2018 Nov 13. No abstract available.

PMID:
30317662
4.

Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients.

Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, Chandran V, Das S, Callis-Duffin K, Ellinghaus E, Enerbäck C, Esko T, Franke A, Kang HM, Krueger GG, Lim HW, Rahman P, Rosen CF, Weidinger S, Weichenthal M, Wen X, Voorhees JJ, Abecasis GR, Gladman DD, Nair RP, Elder JT, Tsoi LC.

Nat Commun. 2018 Oct 9;9(1):4178. doi: 10.1038/s41467-018-06672-6.

5.

Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L.

Br J Dermatol. 2018 Oct;179(4):984-986. doi: 10.1111/bjd.16737. Epub 2018 Jul 20. No abstract available.

PMID:
29747219
6.

Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.

Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Callis Duffin K, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Hüffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Löhr S, Mrowietz U, Müller-Nurayid M, Nöthen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN.

Hum Mol Genet. 2017 Nov 1;26(21):4301-4313. doi: 10.1093/hmg/ddx328.

7.

Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants.

Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, Ellinghaus E, Barker JN, Chandran V, Dand N, Duffin KC, Enerbäck C, Esko T, Franke A, Gladman DD, Hoffmann P, Kingo K, Kõks S, Krueger GG, Lim HW, Metspalu A, Mrowietz U, Mucha S, Rahman P, Reis A, Tejasvi T, Trembath R, Voorhees JJ, Weidinger S, Weichenthal M, Wen X, Eriksson N, Kang HM, Hinds DA, Nair RP, Abecasis GR, Elder JT.

Nat Commun. 2017 May 24;8:15382. doi: 10.1038/ncomms15382.

8.

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.

Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS.

J Am Acad Dermatol. 2017 Feb;76(2):290-298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28. Review.

9.

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Chavers S, Naessens D, Sermon J, Krueger GG.

J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1148-58. doi: 10.1111/jdv.13611. Epub 2016 Mar 30.

10.

microRNAs in Psoriasis.

Hawkes JE, Nguyen GH, Fujita M, Florell SR, Callis Duffin K, Krueger GG, O'Connell RM.

J Invest Dermatol. 2016 Feb;136(2):365-371. doi: 10.1038/JID.2015.409. Review.

11.

Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.

Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT.

Am J Hum Genet. 2015 Dec 3;97(6):816-36. doi: 10.1016/j.ajhg.2015.10.019. Epub 2015 Nov 28.

12.

Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis.

Blauvelt A, Armstrong AW, Krueger GG.

J Drugs Dermatol. 2015 Aug;14(8):805-12.

PMID:
26267724
13.

Desired Improvement Tool (DIT): A tool to assess desire for improvement in psoriasis patients.

Zaghi D, Weir C, Ying J, Carlin C, Greene T, DeShazo R, Callis Duffin K, Krueger GG.

J Dermatolog Treat. 2016;27(1):27-30. doi: 10.3109/09546634.2015.1050351. Epub 2015 Aug 6.

PMID:
26247843
14.

Quality of life assessment in cosmetics: specificity and interest of the international BeautyQol instrument.

Beresniak A, Auray JP, Duru G, Aractingi S, Krueger GG, Talarico S, Tsutani K, Dupont D, de Linares Y.

J Cosmet Dermatol. 2015 Sep;14(3):260-5. doi: 10.1111/jocd.12156. Epub 2015 Jul 2.

PMID:
26133392
15.

Impact of pigmentary disorders on quality of life in Japan: Interest of the BeautyQoL instrument.

Beresniak A, Auray JP, Duru G, Aractingi S, Krueger GG, Talarico S, Adam AS, Piot B, Dupont D, de Linares Y.

J Cosmet Laser Ther. 2015;17(6):313-7. doi: 10.3109/14764172.2015.1039034. Epub 2015 Jul 2.

PMID:
25968164
16.

Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci.

Tsoi LC, Spain SL, Ellinghaus E, Stuart PE, Capon F, Knight J, Tejasvi T, Kang HM, Allen MH, Lambert S, Stoll SW, Weidinger S, Gudjonsson JE, Koks S, Kingo K, Esko T, Das S, Metspalu A, Weichenthal M, Enerback C, Krueger GG, Voorhees JJ, Chandran V, Rosen CF, Rahman P, Gladman DD, Reis A, Nair RP, Franke A, Barker JNWN, Abecasis GR, Trembath RC, Elder JT.

Nat Commun. 2015 May 5;6:7001. doi: 10.1038/ncomms8001.

17.

Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility.

Yin X, Low HQ, Wang L, Li Y, Ellinghaus E, Han J, Estivill X, Sun L, Zuo X, Shen C, Zhu C, Zhang A, Sanchez F, Padyukov L, Catanese JJ, Krueger GG, Duffin KC, Mucha S, Weichenthal M, Weidinger S, Lieb W, Foo JN, Li Y, Sim K, Liany H, Irwan I, Teo Y, Theng CT, Gupta R, Bowcock A, De Jager PL, Qureshi AA, de Bakker PI, Seielstad M, Liao W, Ståhle M, Franke A, Zhang X, Liu J.

Nat Commun. 2015 Apr 23;6:6916. doi: 10.1038/ncomms7916.

18.

Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.

Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):267-74. doi: 10.1002/acr.22576.

19.

Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

Gottlieb AB, Kalb RE, Langley RG, Krueger GG, de Jong EM, Guenther L, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Menter A.

J Drugs Dermatol. 2014 Dec;13(12):1441-8.

PMID:
25607786
20.

Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.

Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin K.

Br J Dermatol. 2015 Jul;173(1):272-4. doi: 10.1111/bjd.13645. Epub 2015 May 18. No abstract available.

PMID:
25557081
21.

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators.

Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. Epub 2015 Mar 22.

22.

Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.

Takeshita J, Wang S, Shin DB, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Robertson AD, Linn KA, Shinohara RT, Troxel AB, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2014 Dec;71(6):1167-75. doi: 10.1016/j.jaad.2014.08.003. Epub 2014 Sep 24.

23.

Fine mapping of eight psoriasis susceptibility loci.

Das S, Stuart PE, Ding J, Tejasvi T, Li Y, Tsoi LC, Chandran V, Fischer J, Helms C, Duffin KC, Voorhees JJ, Bowcock AM, Krueger GG, Lathrop GM, Nair RP, Rahman P, Abecasis GR, Gladman D, Elder JT.

Eur J Hum Genet. 2015 Jun;23(6):844-53. doi: 10.1038/ejhg.2014.172. Epub 2014 Sep 3.

24.

Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes.

Okada Y, Han B, Tsoi LC, Stuart PE, Ellinghaus E, Tejasvi T, Chandran V, Pellett F, Pollock R, Bowcock AM, Krueger GG, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Nair RP, Abecasis GR, Gladman DD, Elder JT, de Bakker PI, Raychaudhuri S.

Am J Hum Genet. 2014 Aug 7;95(2):162-72. doi: 10.1016/j.ajhg.2014.07.002. Epub 2014 Jul 31.

25.

Work productivity loss and fatigue in psoriatic arthritis.

Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, Clegg DO.

J Rheumatol. 2014 Aug;41(8):1670-4. doi: 10.3899/jrheum.140259. Epub 2014 Jul 15.

PMID:
25028377
26.

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.

Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2014 Oct;71(4):633-41. doi: 10.1016/j.jaad.2014.05.001. Epub 2014 Jun 11.

27.

Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.

Chung J, Callis Duffin K, Takeshita J, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Edson-Heredia E, Gelfand JM.

J Am Acad Dermatol. 2014 Oct;71(4):623-32. doi: 10.1016/j.jaad.2014.04.063. Epub 2014 Jun 2.

28.

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A.

Ann Rheum Dis. 2014 Sep;73(9):1689-94. doi: 10.1136/annrheumdis-2013-204902. Epub 2014 Apr 19.

29.

Diagnosing and treating psoriatic arthritis: an update.

Boehncke WH, Qureshi A, Merola JF, Thaçi D, Krueger GG, Walsh J, Kim N, Gottlieb AB.

Br J Dermatol. 2014 Apr;170(4):772-86. doi: 10.1111/bjd.12748. Review.

PMID:
24266754
30.

Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice.

Duffin KC, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, Shin DB, Van Voorhees AS, Gelfand JM.

Br J Dermatol. 2014 Mar;170(3):672-680. doi: 10.1111/bjd.12745.

31.

Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.

Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, Gelfand JM, Krueger GG, Duffin KC.

J Am Acad Dermatol. 2013 Dec;69(6):931-7. doi: 10.1016/j.jaad.2013.07.040. Epub 2013 Sep 17.

PMID:
24054760
32.

Psoriasis and the obesity epidemic: the effect of weight loss.

Caglia MT, Krueger GG.

JAMA Dermatol. 2013 Jul;149(7):786-7. doi: 10.1001/jamadermatol.2013.4512. No abstract available.

PMID:
23752654
33.

Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply.

Gelfand JM, Wang S, Takeshita J, Robertson AD, Krueger GG, Callis Duffin K, Van Voorhees AS.

JAMA Dermatol. 2013 Apr;149(4):491. doi: 10.1001/jamadermatol.2013.2846. No abstract available.

34.

Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.

Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1666-73. doi: 10.1002/acr.22044.

35.

The Dermatology Foundation: partnerships and programs focused on the future.

Fairley JA, Krueger GG, Lessin SR, Leyden JJ, McBurney EI, Orlow SJ, Tharp MD, Voorhees JJ, Wintroub BU, Yancey KB.

J Invest Dermatol. 2013 Apr;133(4):861-2. doi: 10.1038/jid.2013.15. No abstract available.

36.

Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis.

Walsh JA, Callis Duffin K, Krueger GG, Clegg DO.

J Rheumatol. 2013 Mar;40(3):287-93. doi: 10.3899/jrheum.120836. Epub 2013 Feb 1.

PMID:
23378465
37.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M.

Dermatol Ther (Heidelb). 2012 Dec;2(1):2. doi: 10.1007/s13555-012-0002-x. Epub 2012 Mar 30.

38.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1.

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M.

Dermatol Ther (Heidelb). 2012 Dec;2(1):1. doi: 10.1007/s13555-012-0001-y. Epub 2012 Mar 17.

39.

Validation of a new international quality-of-life instrument specific to cosmetics and physical appearance: BeautyQoL questionnaire.

Beresniak A, de Linares Y, Krueger GG, Talarico S, Tsutani K, Duru G, Berger G.

Arch Dermatol. 2012 Nov;148(11):1275-82. doi: 10.1001/archdermatol.2012.2696.

PMID:
23165832
40.

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.

Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, Mudivarthy S, Xu W, Mack M, Xu Z, Beutler A.

Ann Rheum Dis. 2013 Nov;72(11):1777-85. doi: 10.1136/annrheumdis-2012-202035. Epub 2012 Nov 17.

41.

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.

Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B.

J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1252-61. doi: 10.1111/j.1468-3083.2012.04705.x. Epub 2012 Nov 16.

PMID:
23157612
42.

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, Kang HM, Allen MH, McManus R, Novelli G, Samuelsson L, Schalkwijk J, Ståhle M, Burden AD, Smith CH, Cork MJ, Estivill X, Bowcock AM, Krueger GG, Weger W, Worthington J, Tazi-Ahnini R, Nestle FO, Hayday A, Hoffmann P, Winkelmann J, Wijmenga C, Langford C, Edkins S, Andrews R, Blackburn H, Strange A, Band G, Pearson RD, Vukcevic D, Spencer CC, Deloukas P, Mrowietz U, Schreiber S, Weidinger S, Koks S, Kingo K, Esko T, Metspalu A, Lim HW, Voorhees JJ, Weichenthal M, Wichmann HE, Chandran V, Rosen CF, Rahman P, Gladman DD, Griffiths CE, Reis A, Kere J; Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2, Nair RP, Franke A, Barker JN, Abecasis GR, Elder JT, Trembath RC.

Nat Genet. 2012 Dec;44(12):1341-8. doi: 10.1038/ng.2467. Epub 2012 Nov 11.

43.

Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists' perspective: a report from the GRAPPA 2011 annual meeting.

Armstrong AW, Callis Duffin K, Garg A, Gelfand JM, Gottlieb AB, Krueger GG, Qureshi AA, Rosen CF.

J Rheumatol. 2012 Nov;39(11):2204-10. doi: 10.3899/jrheum.120825.

PMID:
23118289
44.

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab.

Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, Murphy FT, Papp K, Gomez-Reino JJ, Mack M, Beutler A, Gladman D, Kavanaugh A.

Ann Rheum Dis. 2013 Jan;72(1):83-8. doi: 10.1136/annrheumdis-2012-201697. Epub 2012 Sep 12.

45.

Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.

Abuabara K, Wan J, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, Krueger GG, Callis Duffin K, Gelfand JM.

J Am Acad Dermatol. 2013 Feb;68(2):262-9. doi: 10.1016/j.jaad.2012.07.007. Epub 2012 Aug 19.

46.

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand JM.

J Am Acad Dermatol. 2013 Jan;68(1):64-72. doi: 10.1016/j.jaad.2012.06.035. Epub 2012 Jul 28.

47.

Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis.

Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, Goldbach-Mansky R, Lowes MA, Peddle L, Chandran V, Liao W, Rahman P, Krueger GG, Gladman D, Elder JT, Menter A, Bowcock AM.

Am J Hum Genet. 2012 May 4;90(5):796-808. doi: 10.1016/j.ajhg.2012.03.013. Epub 2012 Apr 19.

48.

Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.

Wan J, Abuabara K, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, Krueger GG, Callis Duffin K, Gelfand JM.

Arch Dermatol. 2012 Apr;148(4):539-41. doi: 10.1001/archdermatol.2011.1399. No abstract available.

49.

Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.

Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS.

Arch Dermatol. 2012 Apr;148(4):487-94. doi: 10.1001/archdermatol.2012.370.

50.

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.

Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gómez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A.

Arthritis Rheum. 2012 Aug;64(8):2504-17. doi: 10.1002/art.34436.

Supplemental Content

Loading ...
Support Center